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Pediatric glioblastomas (pGBM), although rare, are one of the leading causes of cancer-
related deaths in children, with tumors essentially refractory to existing treatments. Here,
we describe the use of conventional and advanced in vivomagnetic resonance imaging
(MRI) techniques to assess a novel orthotopic xenograft pGBMmouse (IC-3752GBM
patient-derived culture) model, and to monitor the effects of the anti-cancer agent OKN-007
as an inhibitor of pGBM tumor growth. Immunohistochemistry support data is also pre-
sented for cell proliferation and tumor growth signaling. OKN-007 was found to significantly
decrease tumor volumes (p<0.05) and increase animal survival (p<0.05) in all OKN-007-
treated mice compared to untreated animals. In a responsive cohort of treated animals,
OKN-007 was able to significantly decrease tumor volumes (p<0.0001), increase survival
(p<0.001), and increase diffusion (p<0.01) and perfusion rates (p<0.05). OKN-007 also sig-
nificantly reduced lipid tumor metabolism in responsive animals [(Lip1.3 and Lip0.9)-to-cre-
atine ratio (p<0.05)], as well as significantly decrease tumor cell proliferation (p<0.05) and
microvessel density (p<0.05). Furthermore, in relationship to the PDGFRα pathway, OKN-
007 was able to significantly decrease SULF2 (p<0.05) and PDGFR-α (platelet-derived
growth factor receptor-α) (p<0.05) immunoexpression, and significantly increase decorin
expression (p<0.05) in responsive mice. This study indicates that OKN-007 may be an
effective anti-cancer agent for some patients with pGBMs by inhibiting cell proliferation and
angiogenesis, possibly via the PDGFRα pathway, and could be considered as an additional
therapy for pediatric brain tumor patients.
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Introduction
High grade gliomas (HGG) represent one of the most common central nervous system (CNS)
tumors among adults. This contrasts significantly to the pediatric population where HGGs
only comprise approximately 8–12% of all primary CNS tumors [1]. These tumors are classi-
fied by the World Health Organization (WHO) as either grade III or IV meaning that they are
highly malignant tumors with characteristic features such as hypercellularity, nuclear atypia,
and high mitotic activity with or without microvascular proliferation and necrosis [2]. The
most common pediatric HGGs include anaplastic astrocytoma (WHO grade III) and glioblas-
toma (GBM; WHO grade IV). Pediatric glioblastoma (pGBM) is one of the leading causes of
cancer-related deaths in children [3] with a median overall survival for patients of 11 months
[4]. Despite improvements in neurosurgery, radiotherapy, and chemotherapy, the outcome for
children with pediatric HGG remains poor [5]. No effective chemotherapy regimens have been
identified for any pediatric HGG yet [5]. Furthermore, novel molecularly targeted agents have
demonstrated little efficacy in early phase clinical trials [6–8], highlighting the need for new
treatment approaches.
Similarly, the improvement of in vitro and in vivomodels for pediatric HGGs is also needed.
Tumor cell lines and animal models derived from CNS tumors are essential tools to study the
biology of the disease, to comprehend the mechanisms of resistance to therapy, and to carry
out preclinical therapeutic testing. There is abundant information on animal models of adult
HGG [9–11], including chemically induced, genetically engineered mice, and xenograft models
[9]. However, to date only a few pediatric GBMmodels have been established and/or character-
ized [12–14].
We have shown that the anti-cancer agent OKN-007 (OKlahoma Nitrone-007; disodium 4-
[(tert-butyl-imino) methyl] benzene-1,3-disulfonate N-oxide or disufenton) is very effective
against adult gliomas in preclinical models [11,15,16], and it is currently undergoing clinical
trial assessment as a new investigational drug for recurrent adult glioblastomas. OKN-007 is a
small molecule that can traverse the blood-brain barrier and has anti-inflammatory, antioxi-
dant, and proapoptotic properties [17,18]. In an orthotopic rat F98 glioma model and a human
U87 xenograft model in athymic rats, OKN-007 significantly increased the survival of treated
versus untreated rats [16]. Tumor volumes in both of these models were significantly decreased
in treated compared to untreated animals based on magnetic resonance imaging (MRI) assess-
ment [16]. Immunohistochemistry (IHC) assessment of commonly studied tumor markers for
cell proliferation or differentiation, hypoxia, angiogenesis, and apoptosis indicated that OKN-
007 was able to significantly decrease cell proliferation (glucose transporter 1 (Glut-1) and the
cell proliferation marker, MIB-1) but not cell differentiation (carbonate anhydrase IX), decrease
angiogenesis (microvessel density (MVD; measured as levels of the endothelial marker, CD-31),
but not the vascular endothelial growth factor (VEGF)), decrease hypoxia (hypoxia inducible
factor 1 α (HIF-1α)), and increase apoptosis (cleaved caspase 3) compared with untreated con-
trols [16]. OKN-007-induced decreases in Glut-1 and HIF-1α levels seemed to be similar in
both F98 and U87 glioma models, whereas increased apoptosis seemed to be more elevated in
the F98 gliomas compared to the U87 tumors [16]. We concluded that OKN-007 has the ability
to cause glioma regression in aggressive rodent tumor models (F98 and U87), as well as in mod-
erate gliomas (C6) [11,15,16]. Support for the anti-cancer effect of OKN-007 via the TGFβ1
pathway was recently reported by Zheng et al. (2013), where they found that OKN-007 mediates
its antitumor effect in HCC cells (Huh7) via the suppression of TGFβ1/SMAD2 and Hedgehog/
GLI1 signaling by inhibiting sulfatase 2 (SULF2) enzymatic activity [19].
PDGFRα is the most frequent target of focal amplification in pediatric HGGs [20–23].
Somatic mutations of PDGFRα have been also recently reported in pediatric HGGs [22–24]. It
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is also known that the SULF2 gene expression is correlated with PDGFRα expression [25]. Sim-
ilarly to SULF2, decorin is also associated to the PDGFRα pathway [26]. Since it was previously
shown that OKN-007 could affect SULF2 activity, we thought that perhaps this agent could be
effective against pediatric HGGs.
MRI has been used in preclinical [12] and clinical [27–32] studies to diagnose and predict
therapy outcomes for pediatric GBMs. The techniques most commonly used include in vivo 1H
magnetic resonance spectroscopy (1H-MRS) [33–35], diffusion-weighted imaging (DWI) [36],
and arterial spin labeling perfusion (ASL) [37]. 1H-MRS has been used in research and clinical
settings to measure metabolite levels in the brain, and is well suited to perform the diagnosis,
characterization, and assessment of tumor response to treatment [38]. DWI can qualitatively
and quantitatively assess molecular motion on the basis of organization of tissue microstruc-
tures by characterizing water mobility [39], and can provide a more complete evaluation of cel-
lular and metabolic information about human brain cancer [40]. ASL allows the assessment of
measuring tumor blood flow [41], which assists in the characterization of tumor grade [37]
and response to cancer therapy [42].
Here we describe the MRI characterization of a novel orthotopic xenograft pediatric HGG
mouse (IC-3752GBM patient-derived primary culture) model and the effects of OKN-007 to
inhibit in vivo pediatric glioblastoma IC-3752GBM tumor growth using conventional (mor-
phological imaging) and advanced MRI techniques (1H-MRS, DWI, and ASL). Immunohisto-
chemical staining was also used to evaluate the levels of tumor-related proteins and to assess
tumor cell proliferation. To the best of our knowledge, the current study is the first report of
MRI characterization of an orthotopic xenograft murine model of pGBM, and the assessment
of the anti-cancer agent, OKN-007, in a pGBMmodel.
Materials and Methods
Ethics Statement
All experiments of the current study were performed following a human protocol approved by
the Institutional Review Board (IRB) at Baylor College of Medicine as well as an animal proto-
col approved by the Institutional Animal Care and Use Committee (IACUC) of Baylor College
of Medicine and the IACUC of the Oklahoma Medical Research Foundation. For human tissue
samples, signed informed consent was obtained from all patients or their legal guardians prior
to sample acquisition.
Brain tumor specimen
A fresh tumor specimen (3752GBM), from a 5-year-old female who underwent craniotomy at
the Texas Children's Hospital, was obtained in a cryostat laboratory with signed consent fol-
lowing an Institutional Review Board-approved protocol (H-4844). Final pathological diagno-
sis was consistent with pediatric glioblastoma (pGBM) [43]. The tumor sample was directly
implanted into right cerebral cortex of immunedeficient mice (Baylor College of Medicine
IACUC # AN-4548). Xenograft tumor cells harvested from donor mice were passaged in nude
mice via six subsequent implantations as we described previously [43,44].
Intracranial mouse brain tumor model
The passaged pediatric glioblastoma culture IC-3752GBM was implanted intracerebrally in
athymic nude mice (n = 24) (OMRF IACUC protocols # 13–51 and # 13–53). The heads of
anesthetized mice were immobilized (stereotaxic unit; Kopf Instruments, Tujunga, CA), and
with aseptic techniques, a 1 mm burr hole was drilled in the skull 1 mm anterior and 2 mm
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lateral to the bregma on the left or right side. A 20 μL gas-tight Hamilton syringe was used to
inject 5–10 × 106 IC-3752GBM cells/mL suspended in 4 μL in cell culture media with 1.0% aga-
rose into the right or left frontal lobe at a depth of 1.5 mm relative to the dural surface in a ste-
reotaxic unit. Analgesia (Buprenex, i.p. injection) was used following the cell implantation
procedure for pain relief during recovery. The cell lines were maintained and expanded imme-
diately prior to inoculation. Following injection, the skin was closed with surgical sutures. The
animals were divided into two groups: OKN-007–treated (n = 12) and untreated (n = 12)
groups. Both groups were stratified to ensure that tumor sizes were similar before treatment
started in the treated group. The IC-3752GBM primary culture was not passaged more than six
times in mice.
OKN-007 treatment
OKN-007 (Ryss Laboratories, Union City, CA) was administered to the mice in their drinking
water at a concentration of 150 mg/kg/day (0.20% w/v for a 20g mouse). The treatment started
when the tumor volumes were between 10 and 15 mm3, and was administered continuously
until the end of the study. Mice receiving normal drinking water were used as untreated con-
trols. The amount of OKN-007 consumed by each mouse, which were housed in separate
cages, was determined by weighing water bottles each day. No significant deviation was
observed in the volume of liquid uptake of compound in these mice. The average intake of
OKN-007 was approximately 130–150 mg/kg/day for all mice. For the entire study, the thera-
peutic response to OKN-007 was evaluated as either responsive (OKN-007-R) or non-respon-
sive (OKN-007-NR). Mortality was recorded daily during the study period to calculate the
percentage survival of all animals. All animals were humanely euthanized (CO2 asphyxiation)
when they met tumor burden criteria (tumors 150 mm3) and/or showed signs of illness,
weight loss, poor body condition, porphyria, hypoactivity, restlessness, aggressiveness, ataxia,
shallow, rapid and/or labored breathing, cachexia, failure to respond to stimuli, lack of inquisi-
tiveness, vocalization, seizures, hunched posture and ruffled fur). Animals were monitored
twice daily.
Magnetic resonance techniques
Morphological imaging. Nude mice were anesthetized and positioned in a stereotaxic
cradle. A 30-cm horizontal bore Bruker Biospin magnet operating at 7 Tesla (T; Bruker
BioSpin GmbH, Karlsruhe, Germany), was used with a S116 gradient set to perform all MRI
experiments. An EPI (echo planar imaging) transceiver 1H 50W coil with a 38.0 mm inner
diameter was used for signal transmission and detection. Multiple-slice, multiple echo
(MSME) imaging (FOV = 2.50 x 2.50 cm2, TR = 2000 ms, TE = 17.5 or 58.2 ms, matrix = 192,
averages = 2, slices = 16, slice thickness = 1 mm) was used to calculate tumor volumes and to
inspect tumor morphology. Multi slice spin echo T1-weighted images (TR = 1000.0 ms,
TE = 14 ms, FOV = 2.50 × 2.50 cm2, averages = 2, slices = 16, matrix size = 256 × 256) were
also performed and acquired before and 15 min after intravenous contrast agent injection
(Gd-DTPA, Magnevist, Bayer Inc., Wayne, NY, USA; 0.4mmol/kg).
1H-MR Spectroscopy. 1H-MRS was acquired using a PRESS (Point REsolved SpectroS-
copy) sequence with a TE of 24.0 ms, a TR of 2500.0 ms, 512 averages, and a spectral width of
4006 Hz. A non-suppressed MR spectrum was acquired beforehand by applying eddy-current
correction to maximize signal intensity and decrease the peak linewidths. Water was sup-
pressed with a VAPOR (variable power radio frequency pulses and optimized relaxation
delays) suppression scheme. In all cases, the peak width (full width at half maximum) of the
water peak was less than 30 Hz following localized shimming, which was conducted by using
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first and second order adjustments with Fastmap. A cubic voxel of 2.0 x 2.0 x 2.0 mm3 was
positioned in either the tumor or the contralateral normal brain tissue, while maximizing the
amount of tumor tissue present in the voxel at all times.
To analyze the MRS data, an in-house Mathematica program was used (version 6.0, Wol-
fram Research, Champaign, IL, USA). The spectra were scaled in ppm by calibrating against
the water peak (4.78 ppm). The major brain metabolic peaks were identified as: N-acetylaspar-
tate (NAA) at 2.02 ppm, choline (Cho) at 3.22 ppm, creatine (Cre) at 3.02 ppm, and mobile lip-
ids at 1.3 ppm (Lip1.3) for the methylene group (-CH2-) and 0.9 ppm (Lip0.9) for the methyl
group (-CH3) in the tumor tissue. The peak area measurements of the metabolites were used to
calculate the following ratios: tumor NAA to tumor Cho (NAAt/Chot), tumor Cho to contra-
lateral (normal tissue) Cre (Chot/Cren), tumor Cho to tumor NAA (Chot/NAAt), tumor Lip0.9
to contralateral Cre (Lip0.9t/Cren), and tumor Lip1.3 to contralateral Cre (Lip1.3t/Cren).
Diffusion-Weighted Imaging. A coronal axial multi-slice DWI sequence covering the
entire tumor was performed using an echo planar imaging—based pulse sequence with the fol-
lowing parameters: TR = 4000 ms, TE = 51.1 ms, matrix size = 128 × 128, slice thickness =
1mm, diffusion gradient duration = 4 ms, diffusion gradient separation = 14 ms. Five images
were obtained with different gradient scalings, resulting in b-values of 100, 200, 500, 700, and
850 s/mm−2. ADC maps were generated for all the slices in which the tumor was observed. The
apparent diffusion coefficient (ADC) values were obtained by drawing a single freehand ROI
along the border of the tumor normalized to the contralateral normal brain.
Arterial spin-labeling perfusion. Perfusion maps were obtained on a single axial slice of
the brain located on the point of the rostro—caudal axis where the tumor had the largest cross-
section. The imaging geometry was a 25.6 × 25.6 mm2 field-of-view (FOV) of 2 mm in thick-
ness, with a single shot echo-planar encoding over a 64 × 64 matrix. An echo time (TE) of 13.5
ms, a repetition time (TR) of 18 s, and an inversion time (TIR) of 26.0 ms were used, and
images were not submitted to time averaging. To obtain perfusion contrast, the flow alternating
inversion recovery scheme was used. Briefly, inversion recovery images were acquired using a
slice-selective inversion of the same geometry as the imaging slice or a nonselective inversion
slice concentric with the imaging slice with a slice package margin of 5.0 mm. For each type of
inversion, 22 images were acquired with inversion times evenly spaced from 26.0 ms to 8,426.0
ms (with an increment of 400 ms between each TIR). CBV (cerebral blood flow) values were
obtained by drawing a single freehand ROI along the border of the tumor normalized to the
contralateral normal brain to obtain normalized relative CBF (rCBF) values. Negative ASL
CBF values were assumed to be zero [45].
Gross and microscopic histology
Necropsies were performed on all mice. The extent of tumor at necropsy was evaluated by
gross and microscopic examination of the brain for each animal from the untreated and OKN-
007–treated groups. Brain tissues were fixed in 10% phosphate buffered formalin, embedded in
paraffin, serially sectioned at 4 μm, and were stained with hematoxylin eosin (H&E) for histo-
logical examination.
Immunohistochemistry
Immunohistochemical staining was performed using an automated immunostainer (Leica,
Bond-III, Leica, Buffalo Grove, IL) with the following primary polyclonal antibodies: platelet-
derived growth factor receptor alpha (PDGFRα) (1:1000 dilution, rabbit polyclonal, clone
ab61219, ABCAM), decorin (1:500 dilution, rabbit polyclonal, clone LS-B 8177 / 45156),
LSBIO LifeSpan BioSciences), heparan sulfate sulfatase SULF2 (1:100 dilution, rabbit
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polyclonal, clone AV49338, Sigma Aldrich), and CD31 (1:25 dilution, rabbit polyclonal, clone
ab28364, ABCAM, Ki-67 (1:100 dilution, rabbit polyclonal, clone PA5-19462, Thermo Fisher
Scientific, IL). All antibodies were initially optimized on control tissues, and positive and nega-
tive controls were processed in parallel to the tissue sections.
IHC Scoring
All IHCs were analyzed using the Aperio ScanScope Image Analysis System (Aperio, Vista,
CA). PDGFRα, SULF2, and decorin IHCs were analyzed using a Positive Pixel Count algo-
rithm with the Aperio ImageScope viewer. Only areas containing tumor tissue were analyzed
for IHC expression. Areas without tumor tissue and areas with necrosis or significant artifacts
(e.g. tissue folding) were deselected and excluded from analysis. The number of positive pixels
from regions-of-interest (ROIs) with high expression were divided by the total number of pix-
els (negative and positive) in the analyzed area, and multiplied by 100, to derive the percentage
of positive pixels.
Microvessel density (MVD, number of vessels per mm2) and Mean Vessel Area (MVA, Vas-
cular area/2 + lumen area), using CD31 as a marker, were determined using an Aperio micro-
vessel analysis algorithm. Three representative non-overlapping regions of interest (ROIs) for
tumor samples were randomly selected, and the MVD and MVA were quantified for each ani-
mal from both untreated and OKN-007–treated groups.
An Aperio ScanScope Image Analysis System was also used to determine the KI-67 labeling
index (Ki-67 LI). Three ROIs with the highest number of labeled nuclei were identified in each
case. Ki-67 LI was determined by counting 1000 cells and expressing this as the number of
labeled cells per 1000 cells [46] for each animal from both untreated and OKN-007–treated
groups. Labeled cells adjacent to or within necrotic areas were also excluded while counting the
Ki-67 LI. The means and standard deviations of Ki-67 LI were determined for each group.
Statistical Analysis
Statistical analyses were performed using Graph Pad Prism 6 (GraphPad Prism 6 Software, San
Diego, CA, USA). All p values<0.05 were considered statistically significant. Tumor volumes,
metabolite peak length ratios [(NAAt/Chot), (Chot/Cren), (Chot/NAAt), (Lip0.9t/Cren), and
(Lip1.3t/Cren)], normalized ADC, rCBF, Ki-67 LI, and immunoexpression of PDGFRα,
SULF2, and decorin were reported as means ± standard deviations. For statistical analysis,
Student t-tests (independent-samples, two-tailed t-test) were used to assess the differences
between means of the normal, untreated, and OKN-007 treated pediatric IC-3752GBM glioma
mice. Kaplan-Meier survival curves and a Log-rank (mantel-cox) test were used to compare
the survival times among the untreated and OKN-007 treated groups.
Results
Macroscopic, histological, immunohistochemical and MRI characteristics of the novel orthoto-
pic xenograft pediatric glioblastoma (pGBM) model IC-3752GBM and the effects of OKN-007
to inhibit IC-3752GBM tumor culture growth were described in this report.
Gross and microscopic characteristics of the IC-3752GBM pGBMmodel are presented in
Fig 1A–1E. Macroscopically the tumors were characterized as a yellowish gray, poorly demar-
cated mass, with multifocal areas of necrosis and hemorrhage. Histological examination
revealed poorly demarcated, unencapsulated infiltrating neoplasm with marked cell atypia,
high mitotic index, and multifocal areas of necrosis and hemorrhage.
Animal survival was assessed by comparing OKN-007–treated animals with untreated ani-
mals (Fig 2). Overall, OKN-007 was found to significantly increase animal survival (p<0.0223)
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(median survival of 25.5 days) compared to untreated tumor-bearing mice (median survival of
19.5 days). The total OKN-007-treated survival data seemed to depict two treatment response
cohorts. For instance, it was found that six animals responded to the OKN-007 treatment and
demonstrated significantly longer survival times (p = 0.0002) (median survival of 33 days)
when compared with untreated animals (n = 12). Conversely, six other pGBMmice did not
seem to respond to the OKN-007 therapy, and showed no statistical difference (p = 0.3392)
when compared to the untreated group. The non-responsive OKN-007-treated mice seemed to
have a median survival (19 days) that was similar to the median survival for the untreated
tumor-bearing mice.
To calculate the whole tumor volume in some animals, MSME T1-weighted images were
performed and acquired before (Fig 3A) and 15 min after (Fig 3B) intravenous contrast agent
Fig 1. Gross andmicroscopic pathology of the IC3752 pediatric glioma tumor. (A-B) Formalin fixed
IC3752 pGBM tissue, characterized as a yellowish gray and poorly demarcated mass, with multifocal areas
of necrosis and hemorrhage. (C-E) Histological examination revealed poorly demarcated, unencapsulated,
and invasive neoplasms (E) characterized by marked cell atypia, a high mitotic index (black arrows) (C), and
multifocal areas of necrosis (asterisks) and hemorrhage (plus sign) (D). T = Tumor, B = normal brain. Scale
bar = 200 μm (C-D). Scale bar = 400 μm (E).
doi:10.1371/journal.pone.0134276.g001
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injection (Gd-DTPA, Magnevist, Bayer Inc., Wayne, NY, USA). Fig 3E shows the quantitative
mean IC-3752GBM tumor volumes calculated fromMR images. The total OKN-007-treatment
group was found to significantly decrease tumor volumes (p = 0.0289) compared to untreated
mice (Fig 3E). Based on the survival data which indicated responsive and non-responsive
OKN-007 treatment cohorts, the tumor volume was also separated in terms of treatment
response. Six animals were found to respond to OKN-007 treatment [OKN-007-(R)] and dem-
onstrated significantly smaller tumors (p<0.001) (Fig 3D) when compared with untreated ani-
mals (n = 12) (Fig 3C). It was also found that six pGBMmice found not to respond [OKN-007-
(NR)] to the OKN-007 therapy (based from animal survival data), showed statistical difference
(p = 0.7857) when compared to the untreated group.
For all other investigations, OKN-007-(R) and OKN-007-(NR) treatment groups were
compared to untreated tumor-bearing mice, as not all mice underwent 1H-MRS, DWI, perfu-
sion imaging or IHC assessments. 1H-MRS values were obtained in normal athymic nude
mice (n = 7), and untreated (n = 6) and OKN-007–treated (n = 8) mice bearing IC-3752GBM
gliomas. Fig 4 shows the regions where the single 8mm3 voxel for 1H-MR spectroscopy was
placed in the brains of normal mice (Fig 4A) and mice bearing IC-3752GBM gliomas (Fig
4B). Fig 4C shows that the untreated IC-3752GBM pGBMmice demonstrated significantly
lower NAAt/Chot (p = 0.0001) and higher Chot/Cren (p = 0.0325), Chot/NAAt (p = 0.0075),
Lip0.9t/Cren (p = 0.0363) and Lip1.3t/Cren (p = 0.0009) ratios when compared to the normal
athymic mouse brain. The Lip1.3t/Cren (p = 0.0395), Lip0.9t/Cren (p = 0.0257), Chot/NAAt
(p = 0.0167), and Chot/Cren (p = 0.0254) ratios were significantly lower in the OKN-007-(R)
group than untreated pGBM at the end phase of tumor progression. The OKN-007-(R)
Fig 2. Effect of OKN-007 on percent survival for IC3752 pGBM tumor bearingmice. There was a
significant increase in percent survival for all OKN-007-treated mice (n = 12) (p < 0.05) compared to untreated
tumor-bearing mice (n = 12). Based on the different response cohorts, the OKN-007-treatment group was
further divided into OKN-007-R (responsive) and OKN-007-NR (non-responsive) cohorts. OKN-007-R mice
(n = 6) demonstrated significantly longer survival times (p < 0.001) when compared with UT animals (n = 12).
Conversely, OKN-007-NRmice (n = 6) showed no statistical difference (p > 0.05) when compared to the UT
group.
doi:10.1371/journal.pone.0134276.g002
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Fig 3. Effect of OKN-007 on tumor volumes for IC3752 pGBM tumor bearingmice.Representative
T1-weighted morphological images before (A) and after contrast agent (Gd-DTPA) injection (B) in pGBM-
bearing mice are shown. (A) Before contrast administration the tumor appeared as a mildly hyperintense
mass and it was difficult to demarcate it. (B) Fifteen minutes after the contrast injection the IC3752 pGBM
demonstrates enhancement, delineating the tumor (yellow dashed line). Representative T2-weighted MR
images of UT (C) and OKN-007 (D) treated IC 3752 pGBM-bearing mouse brains. (E) The quantitative
histogram for all mice shows that all OKN-007-treated mice (n = 12) had a significantly decreased tumor
volume (p < 0.05) compared to UT mice (n = 12). Six animals responded to the OKN-007 treatment [OKN-007
(R)] and demonstrated significantly smaller tumors (p < 0.0001) when compared with UT animals (n = 12).
However, six other pGBMmice did not seem to respond [OKN-007 (NR)] to the OKN-007 therapy, and there
was no statistical difference between the UT and OKN-007 (NR) group. Values are represented as
means ± SD. Group comparisons: (1) UT vs. OKN-007 (total); (2) UT vs. OKN-007 (R); and (3) OKN-007 (R)
vs OKN-007 (NR).
doi:10.1371/journal.pone.0134276.g003
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Fig 4. Brain metabolite ratios in normal and untreated vs. OKN-007 treated IC3752 pGBM tumor bearingmice. Representative locations of the 2 x 2x 2
mm3 voxels used to perform 1H-MRS in normal mouse brain (A) and IC3752 pGBM tumor bearing mice (B). (C) The untreated IC3752 pGBMmice
demonstrated a significantly lower NAAt/Chot ratio and higher Chot/Cren (p = 0.0325), Chot/NAAt, Lip0.9t/Cren and Lip1.3t/Cren ratios when compared to
the normal athymic mouse brains. The Lip1.3t/Cren, Lip0.9 t/Cren, Chot/NAAt, and Chot/Cren ratios were significantly lower in the OKN-007-(R) group when
compared to untreated pGBM at the end phase of tumor progression. The OKN-007-(R) group showed a significantly higher NAAt/Chot ratio than the
untreated pGBM. There was no significant difference between the Chot/Cren, NAAt/Chot, Chot/NAAt, and Lip0.9t/Cren ratios for the normal mouse brains
compared to the OKN-007-(R) group. The OKN-007-(R) group showed a significantly higher Lip1.3t/Cren ratio than the normal mouse brain. There was no
significant difference between the NAAt/Chot, Chot/Cren, Chot/NAAt, Lip0.9t/Cren and Lip1.3t/Cren ratios for the untreated compared to the OKN-007-(NR)
groups. Asterisks indicate statistically significant difference (*p < 0.05; ***p<0.01; ***p<0.001; ****p<0.0001). Group comparisons: (1) Normal vs. UT; (2)
UT vs. OKN-007 (R); (3) OKN-007 (R) vs OKN-007 (NR); (4) Normal vs. OKN-007 (R); (5) UT vs. OKN-007 (NR); and (6) Normal vs. OKN-007 (NR).
doi:10.1371/journal.pone.0134276.g004
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group showed a significantly higher NAAt/Chot (p = 0.0492) ratio than the untreated
pGBM. There was no significant difference between the Chot/Cren (p = 0.498), NAAt/Chot
(p = 0.6912), Chot/NAAt (p = 0.4231), and Lip0.9t/Cren (p = 0.6205) ratios of the normal
mouse brain compared to the OKN-007-(R) group. The OKN-007-(R) group showed a sig-
nificantly higher Lip1.3t/Cren (p = 0.0047) ratio than the normal mouse brain. There was no
significant difference between the NAAt/Chot (p = 0.2071), Chot/Cren (p = 0.7101), Chot/
NAAt (p = 0.5362), Lip0.9t/Cren (p = 0.7277) and Lip1.3t/Cren (p = 0.5163) ratios of the
untreated group compared to the OKN-007-(NR) group.
In our study, with the use of DWI, the untreated group showed significantly higher
(p = 0.0060) (1.161 ± 0.04538, n = 11) normalized ADC values in the tumor regions when com-
pared to the normal mice brains (1.003 ± 0.009358, n = 6) (Fig 5A–5G). The OKN-007–R
treated group had significantly higher normalized ADC values (1.296 ± 0.04141, n = 7) com-
pared to the untreated group (p = 0.0432) or the normal mice brains (p = 0.0003). All OKN-
007 treated animals were found to be responsive to the anticancer therapy based on the ADC
ratios when compared to the untreated group (Fig 5G).
When using perfusion imaging, the untreated group showed significantly lower (p< 0.0001)
(0.1372 ± 0.04581, n = 9) rCBF values for the tumor regions when compared to the normal mice
brains (1.036 ± 0.03305, n = 9) (Fig 6A–6G). The OKN-007–R treated group had significantly
higher rCBF values (0.3624 ± 0.06599, n = 4) compared to the untreated group (p = 0.0307) or
lower than the normal mice brains (p = 0.0004). There was no significant difference between
rCBF values in the contralateral regions of OKN-007-R [104.8 ± 30.16 mL/(100g x min), n = 4]
and OKN-007-NR [111.9 ± 34.15 mL/(100g x min), n = 2] or untreated [99.17 ± 19.50 mL/
(100g x min), n = 7] animals (Fig 6G).
Tumor cell proliferation was evaluated via immunoexpression of the anti-Ki-67 antibody. The
Ki-67 LI was significantly lower (p = 0.0181) in the OKN-007–R treated group (64.15 ± 0.5322,
n = 4) than in the untreated group (69.93 ± 1.524, n = 6) (Fig 7A–7C). There was no significant
difference (p = 0.1822) between the Ki-67 LI of the OKN-007–NR (78.33 ± 4.287, n = 2) and
untreated group.
Microvessel density (MVD) were measured via the immunoexpression of the anti-CD31
antibody. The MVD was significantly lower (p = 0.0358) in the OKN-007–R treated group
(12.13 ± 1.648, n = 3) than in the untreated group (20.41 ± 2.737, n = 7) (Fig 8A–8C). There
was no significant difference (p = 0.3092) between the MVD of the OKN-007–NR (22.55 ±
3.014, n = 4) and untreated group.
OKN-007 significantly decreased the immunoexpression of PDGFR-α in the treated
responsive group (p = 0.0429) (28.58 ± 4.743, n = 4) when compared to the untreated animals
(43.82 ± 3.779, n = 6). There was no significant difference (p = 0.1400) between the immunoex-
pression of PDGFR-α of the OKN-007–NR (53.17 ± 3.905, n = 3) and the untreated groups
(Fig 9). Normal brain % PDGFR-α was found to be quite high in areas of tissue where ROIs
were taken from elevated expression levels, and were significantly higher than the untreated or
OKN-007-treated groups. The high % PDGFR-α levels in the normal brain are due to expres-
sion in both the nucleus and cytoplasm, whereas the majority of tumor cells had negative
nuclei. Overall in Fig 9A it can be seen that levels of PDGFR-α are substantially lower than
untreated tumors due to a 21% decrease in cell density which is 972.8 ± 85.8 mm2 (n = 5) for
normal brain compared to 4620 ± 379 mm2 (n = 5) for untreated tumors.
OKN-007 also significantly decreased the immunoexpression of SULF2 in the treated
responsive group (p = 0.0339) (23.99% ± 5.187, n = 4) when compared to the untreated ani-
mals (53.17% ± 7.389, n = 3). There was no significant difference (p = 0.4180) between the
immunoexpression of SULF2 of the OKN-007–NR (45.66% ± 1.686, n = 2) and the untreated
groups (Fig 10). The levels of % SULF-2 in high-expression regions of normal brain were
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significantly less than that found in untreated or OKN-007-treated tumors. The expression of
SULF-2 was significantly decreased in the normal brain because it was expressed predomi-
nantly in the endothelial cells. In this case, the number of negative pixels was higher, and con-
sequently the positivity (Positivity = Positive / Positive + Negative) was decreased.
The immunoexpression of decorin was significantly higher (p = 0.0478) in the OKN-007–R
treated group (22.86 ± 0.1479, n = 2) compared to the untreated animals (11.73 ± 3.438, n = 4).
Fig 5. Effect of OKN-007 on diffusionmeasured as ADC values in IC3752 pGBM tumor bearingmice.
T2-images (top) and diffusion maps (bottom) of normal mouse brain (A-B), untreated IC3752 pGBM (C-D),
and OKN-007-R treated animal (E-F). (G) The untreated group (n = 11) had significantly higher normalized
ADC values for the tumor region when compared to the normal mice brains (n = 6). The OKN-007–R treated
group showed significantly higher normalized ADC values (n = 7) compared to the untreated group and
normal mice brains. Values are represented as means ± SD. Asterisks indicate statistically significant
difference (*p < 0.05; ***p<0.01; ***p<0.001; ****p<0.0001). Group comparisons: (1) Normal vs. UT; (2)
UT vs. OKN-007 (R); (3) OKN-007 (R) vs. OKN-007 (NR); (4) Normal vs. OKN-007 (R); (5) UT vs. OKN-007
(NR); and (6) Normal vs. OKN-007 (NR).
doi:10.1371/journal.pone.0134276.g005
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There was no significant difference (p = 0.0167) between the immunoexpression of decorin for
the OKN-007–NR (18.44 ± 1.128, n = 5) and the untreated groups (Fig 11). The levels of % dec-
orin in high-expression regions of normal brain were significantly higher than that found in
untreated or OKN-007-treated tumors. The high % decorin levels in the normal brain are due
to expression in both the nucleus and cytoplasm, similar to PDGFR-α, and conversely the
majority of tumor cells had negative nuclei. Also taking into consideration the 21% decrease in
Fig 6. Effect of OKN-007 on perfusion ratesmeasured as rCBF in IC3752 pGBM tumor bearingmice.
T2-images (top) and perfusion maps (bottom) of normal mouse brain (A-B), untreated IC3752 pGBM (C-D),
and OKN-007-R treated animal (E-F). (G) The untreated group (n = 9) showed significantly lower rCBF values
for the tumor regions when compared to the normal mice brains (n = 9). The OKN-007–R treated group
(n = 4) showed significantly higher rCBF values compared to the untreated group, and was significantly lower
than normal brain. Values are represented as means ± SD. Asterisks indicate statistically significant
difference (*p < 0.05; ***p<0.01; ***p<0.001; ****p<0.0001). n.s.: not statistically significant. Group
comparisons: (1) Normal vs. UT; (2) UT vs. OKN-007 (R); (3) OKN-007 (R) vs. OKN-007 (NR); (4) Normal vs.
OKN-007 (R); (5) UT vs. OKN-007 (NR); and (6) Normal vs. OKN-007 (NR).
doi:10.1371/journal.pone.0134276.g006
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cell density in normal brain compared to untreated tumors, the overall levels of decorin would
be less overall when considering all areas of tissue.
Discussion
Animal modeling for primary brain tumors has undergone constant development over the last
60 years, and significant improvements have been made recently with the establishment of
highly invasive glioblastoma models through the direct implantation of patient tumors [9,44].
However, animal models for pediatric HGGs are still an underexploited tool to make rapid
advances in human cancer prevention, diagnosis, and therapy.
This is the first description of the macroscopy, histology, immunohistochemistry and MRI
characterizations of the novel orthotopic xenograft pediatric glioblastoma (pGBM) model IC-
3752GBM [43], and assessing the ability of OKN-007 to inhibit IC-3752GBM tumor cell
growth. Previous reports in GBM preclinical models are limited to in vitro 1H-MRS in other
pGBM cell lines [12].
Fig 7. Effect of OKN-007 on cell proliferation in IC3752 pGBM tumor bearingmice.
Immunohistochemistry images of Ki-67 levels in untreated (A) and OKN-007-treated (B) IC3752 pGBM
tumors. (C) Ki-67 LI was significantly lower (p < 0.05) in the OKN-007–R treated group (n = 4) than in the
untreated group (n = 6). There was no significant difference between the Ki-67 LI of the OKN-007–NR (n = 2)
and the untreated groups. Values are represented as means ± SD. Asterisks indicate statistically significant
difference (*p < 0.05). n.s.: not statistically significant. Scale bar = 200 μm. Group comparisons: (1) UT vs.
OKN-007 (R); (2) OKN-007 (R) vs. OKN-007 (NR); and (3) UT vs. OKN-007 (NR).
doi:10.1371/journal.pone.0134276.g007
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The anti-cancer response to OKN-007 in adult glioma models was previously reported by
our group based on morphological (T2-weighted) imaging, bioluminescence imaging, and
immunohistochemistry assessments, in addition to survival data [11,15,16]. The cytotoxic
mechanism of OKN-007 seems to be associated with induced apoptosis in rat F98 and human
U87 xenografts [16]. OKN-007 was found to significantly decrease tumor volumes (p< 0.05),
as measured by MRI, and increase survival (p< 0.001) in F98 glioma-bearing rats [23]. Assess-
ment of the treatment response using other MR parameters, such as 1H-MRS, DWI, and perfu-
sion rates, was also performed by our group in C6 rat gliomas [10,15], but the use of a multi-
parametric approach has not been previously reported for any pediatric glioblastoma model.
From gross examination of the IC-3752GBM pGBM (Fig 1A–1B), the tumors were charac-
terized as a yellowish gray, poorly demarcated mass, with multifocal areas of necrosis.
Fig 8. Effect of OKN-007 onmicrovessel density in IC3752 pGBM tumor bearingmice.Microvessel
density (MVD) was measured via the immuno-expression of CD31. Immunohistochemistry images of CD31
levels in untreated (A) and OKN-007-treated (B) IC3752 pGBM tumors. (C) The MVD was significantly lower
in the OKN-007–R treated group (n = 3) than in the untreated group (n = 7). There was no significant
difference between the MVD for the OKN-007–NR (n = 4) and the untreated groups. The MVA was
significantly lower in the OKN-007–R treated group (n = 3) than in the untreated group (n = 9). There was no
significant difference between the MVA of the OKN-007–NR (n = 3) and the untreated groups. Values are
represented as means ± SD. Asterisks indicate statistically significant difference (*p < 0.05). n.s.: not
statistically significant. Scale bar = 200 μm. Group comparisons: (1) UT vs. OKN-007 (R); (2) OKN-007 (R)
vs. OKN-007 (NR); and (3) UT vs. OKN-007 (NR).
doi:10.1371/journal.pone.0134276.g008
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Fig 9. Effect of OKN-007 on the immunoexpression of PDGFR-α in IC3752 pGBM tumor bearingmice.
(Ai-Ci) Immunohistochemistry expression of PDGFR-α in normal mouse brain, IC3752 pGBMUT, and OKN-
007 treated animals, respectively. (Aii-Cii) Make up images for the immunoexpression of PDGFR-α in normal
mouse brain, IC3752 pGBMUT, and OKN-007 treated animals, respectively. (D) OKN-007 significantly
decreased the immunoexpression of PDGFR-α (%) in the treated responsive group (n = 4) when compared to
the untreated animals (n = 6). There was no significant difference between the immunoexpression of
PDGFR-α of the OKN-007–NR (n = 3) and the untreated groups. % PDGFR-α levels in high-expression areas
within the normal brain tissue were significantly higher than those in UT or OKN-007-treated mice. Values are
represented as means ± SD. Asterisks indicate statistically significant difference (*p < 0.05; **p<0.01;
***p<0.001). n.s.: not statistically significant. Red = positive, blue = negative, white = neutral, background.
Scale bar = 200 μm. Group comparisons: (1) Normal vs. UT; (2) UT vs. OKN-007 (R); (3) OKN-007 (R) vs.
OKN-007 (NR); (4) Normal vs. OKN-007 (R); (5) UT vs. OKN-007 (NR); and (6) Normal vs. OKN-007 (NR).
doi:10.1371/journal.pone.0134276.g009
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Fig 10. Effect of OKN-007 on the immunoexpression of SULF2 in IC3752 pGBM tumor bearingmice.
(Ai-Ci) Immunohistochemistry expression of SULF2 in normal mouse brain, IC3752 pGBMUT, and OKN-007
treated animals, respectively. (Aii-Cii) Make up images for the immunoexpression of SULF2 in normal mouse
brain, IC3752 pGBMUT, and OKN-007 treated animals, respectively. (D) OKN-007 significantly decreased
the immunoexpression of SULF2 (%) in the treated responsive group (n = 4) when compared to the untreated
animals (n = 3). There was no significant difference between the immunoexpression of SULF2 of the OKN-
007–NR (n = 2) and the untreated groups. % SULF-2 levels in high-expression areas within the normal brain
tissue were significantly lower than those in UT or OKN-007-treated mice. Values are represented as
means ± SD. Asterisks indicate statistically significant difference (*p < 0.05; **p < 0.01). n.s.: not statistically
significant. Red = positive, blue = negative, white = neutral, background. Scale bar = 200 μm. Group
comparisons: (1) Normal vs. UT; (2) UT vs. OKN-007 (R); (3) OKN-007 (R) vs. OKN-007 (NR); (4) Normal vs.
OKN-007 (R); (5) UT vs. OKN-007 (NR); and (6) Normal vs. OKN-007 (NR).
doi:10.1371/journal.pone.0134276.g010
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Fig 11. Effect of OKN-007 on the immunoexpression of decorin in IC3752 pGBM tumor bearingmice.
(Ai-Ci) Immunohistochemistry expression of decorin in normal mouse brain, IC3752 pGBMUT, and OKN-007
treated animals, respectively. (Aii-Cii) Make up images for the immunoexpression of decorin in normal mouse
brain, IC3752 pGBMUT, and OKN-007 treated animals, respectively. (D) The immunoexpression of decorin
was significantly higher (p = 0.0478) in the OKN-007–R treated group (22.86 ± 0.1479, n = 2) compared to the
untreated animals (11.73 ± 3.438, n = 4). There was no significant difference (p = 0.0167) between the
immunoexpression of decorin for the OKN-007–NR (18.44 ± 1.128, n = 5) and the untreated groups. %
Decorin levels in high-expression areas within the normal brain tissue were significantly higher than those in
UT or OKN-007-treated mice. Values are represented as means ± SD. Asterisks indicate statistically
significant difference (*p < 0.05; **p<0.01; ***p<0.001; ****p<0.0001). n.s.: not statistically significant.
Red = positive, blue = negative, white = neutral. Scale bar = 200 μm. Group comparisons: (1) Normal vs. UT;
(2) UT vs. OKN-007 (R); (3) OKN-007 (R) vs. OKN-007 (NR); (4) Normal vs. OKN-007 (R); (5) UT vs. OKN-
007 (NR); and (6) Normal vs. OKN-007 (NR).
doi:10.1371/journal.pone.0134276.g011
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Histological examination (Fig 1C–1E) revealed poorly demarcated, unencapsulated infiltrating
neoplasms with marked cell atypia, a high mitotic index, and multifocal areas of necrosis and
hemorrhaging, which is comparable to features for GBM in pediatric patients [2]. We previ-
ously demonstrated that serial passage (up to six times) of patient-derived xenografts of IC-
3752GBM pGBM replicated the histological features and genetic changes (e.g. loss of heterozy-
gosity) associated with the original patient tumor [44].
The survival time of IC-3752GBM pGBMmice was significantly increased in all treated
mice (p<0.05) and the responsive group (p<0.001) after OKN-007 therapy, as we also have
previously reported in adult glioma models [15,16]. The total OKN-007 group had a median
survival of 25.5 days, whereas the OKN-007-R had a mean survival time of 33 days, which were
both longer than the median survival of 19.5 days for the untreated group (Fig 2). In our study,
OKN-007 was able to increase the survival time by 6 days compared to the untreated animals.
Considering that one mouse month is estimated to be*2.6 human years, based on a 4-year
maximum life span [47,48], the increased survival time in human patients could be estimated
to be ~6–7 months.
From contrast-enhanced in vivomorphological MR imaging (Fig 3B), IC-3752GBM pGBM
tumors were characterized as mildly to markedly hyperintense, with poorly defined margins,
and infiltrative tumors, sharing similar MRI characteristics with human glioblastomas [49].
Morphological MR images were also used to determine the volumes of individual tumors, start-
ing on day 25 after the cell implantation, and continuing throughout the entire experiment.
For the entire OKN-007-treatment group, there was a significant decrease in tumor volumes
(p<0.05), compared to untreated mice. Additionally, the therapeutic responses to OKN-007
were evaluated as either responsive (OKN-007-R) or unresponsive (OKN-007-NR). One
cohort of mice were found to respond to OKN-007 treatment [OKN-007-(R)], based on sur-
vival data, and demonstrated significantly smaller tumors (p<0.001) when compared with
untreated animals (Fig 3E). However, there were also non-responsive mice [OKN-007-(NR)]
that seemed to be not affected to the OKN-007 therapy. For the responsive mice, our results
were similar to prior adult glioma studies of our group, which showed that OKN-007 had a
dramatic effect on regressing tumor formation in rat F98 [16] and C6 [11,15], and human U87
xenograft [16] glioma models.
A possible explanation for the varied treatment response may be due to the heterogeneous
nature of the cell population that is being passaged from mice to mice, unlike a homogeneous
cell culture population like what was used in our adult glioma studies. From this study it is
clear that not all of the cells respond appropriately to OKN-007 treatment. Possibly there is a
resistance that develops in some of the cells which overtake the growth of the responsive cells
in the OKN-007-NR group, whereas in the OKN-007-R group the responsive cells predomi-
nate. Further cell sorting studies could be done to isolate these two cell populations, however
distinctive markers that differentiates these two cell types would need to be sought.
We also assessed the OKN-007 treatment response by using other MR parameters, such as
1H-MRS to measure tumor metabolites, DWI to assess structural alterations, and perfusion
rates to evaluate microvascularity alterations. 1H-MRS is a non-invasive technique that mea-
sures the concentration of a variety of biomolecules from a volume of interest [50].
MRS findings have been shown to be closely related to the histological features of glioma
cells and can be used for evaluating tumor differentiation, grading, follow-up and radiotherapy
planning [51–53]. MRS is also a valuable tool for identifying early changes in glioma metabo-
lism and the extent of glioma infiltration [54,55]. The technique is widely available clinically
and easily appended to a standard MRI examination, which is routinely performed at the time
of diagnosis on children with brain tumors [56]. The principal metabolites that can be assessed
by 1H-MRS in brain tumors include choline (Cho, 3.2 ppm), creatine (Cre, 3.0 ppm), N-
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acetylaspartate (NAA, 2.0 ppm), and lipids (Lip; 0.9–1.3 ppm) [55]. Choline is a constituent
molecule associated with the phospholipid metabolism of cell membranes and reflects mem-
brane turnover [57]. Its concentration is slightly greater in white matter than in gray matter
[57]. Increased Cho indicates greater membrane synthesis and cell proliferation [57]. Its con-
centration is markedly increased in cases of brain neoplasms [57]. Phosphocholine and glycer-
ophosphocholine also contribute to the representation of the Cho peak in 1H-MRS [57].
Creatine is a marker of aerobic energy metabolism in brain cells, and is present in larger con-
centrations in the gray matter than in the white [57]. Creatine and phosphocreatine, both of
which contribute to the Cre pool, are found in both neurons and glial cells [57]. Cre and phos-
phocreatine remain relatively stable in vivo, and therefore their peak is often used as an internal
concentration standard [58]. However, recent studies have suggested that the Cre levels may be
altered in human gliomas [59]. N-acetyl aspartate, a free amino acid, is almost exclusively
located in neurons and axons, and is the most prominent signal observed in 1H-MRS for the
CNS. The NAA peak in 1H-MRS is decreased whenever there is neuron loss, such as in gliomas,
ischemia and degenerative diseases [57]. A strong association between 1H-MRS detectable lip-
ids and tumor grade has been reported in adult gliomas [60] and childhood brain tumors [61]
suggesting that high intracellular lipid levels are a non-invasive marker of brain tumor malig-
nancy. Studies on cultured cells, ex-vivo tumor tissue and animal models have shown that an
increase in MRS detectable lipids is associated with cell stress [62], apoptosis [63] and hypoxia
as a result of compromised vascularity [64]. MRS detectable lipids are therefore associated with
several factors known to be present in aggressive tumors that have a poor prognosis.
In our study, we measured the peak areas of Cho, Cre, NAA, Lip0.9, and Lip1.3 in the nor-
mal brain of athymic nude mice and untreated and OKN-007 treated IC-3752GBM pGBM
bearing mice. Those values were used to determine the following ratios: tumor NAA to tumor
Cho (NAAt/Chot), tumor Cho to contralateral Cre (Chot/Cren), tumor Cho to tumor NAA
(Chot/NAAt), tumor Lip0.9 to contralateral Cre (Lip0.9t/Cren), and tumor Lip1.3 to contralat-
eral Cre (Lip1.3t/Cren). The untreated IC-3752GBM pGBMmice demonstrated significantly
lower NAAt/Chot (p< 0.001) and higher Chot/Cren (p< 0.05), Chot/NAAt (p< 0.01), Lip0.9t/
Cren (p< 0.05) and Lip1.3t/Cren (p< 0.001) ratios when compared to the normal athymic
mouse brain (Fig 4C), which corroborates with metabolite profiles observed in human GBM.
Typical 1H-MRS findings for cerebral gliomas includes reduction of NAA, variable levels of Cr,
and an elevation in Cho and lipids, in proportion to glioma grade [65].
The role of mobile lipids in cancer has been the subject of many excellent reviews and arti-
cles [10,11, 64,66–70]. In brain tumors, the elevation of lipid levels usually correlates with
necrosis [66,67,71], and are considered as important biomarkers for diagnosis and monitoring
the effects of treatment response [66]. A number of studies have also demonstrated that an
increase in mobile lipids is associated with the onset of drug-induced apoptosis [62,66]. OKN-
007 significantly reduced the lipid peaks at 1.3ppm (p< 0.05) and 0.9 ppm (p< 0.05) in
treated animals compared to the untreated group, which could be related to a decrease in
tumor necrosis by OKN-007 in treated animals. This anticancer property of OKN-007 may be
very beneficial for GBM patients, since necrosis is caused by tumor hypoxia as a result of
increased cell proliferation and mitotic activity, as well as insufficient tissue perfusion [72], and
it is present in over 85% of cases [73,74].
The IC-3752GBM pGBM bearing mice treated with OKN-007 showed a significantly lower
Chot/NAAt ratio (p< 0.05) than the untreated group. The effect of OKN-007 on the Cho/
NAA ratio in the IC-3752GBM pGBMmodel is remarkable, since it has been reported that the
Cho/NAA ratio provides a sensitive method for detecting differences in tumor growth [75].
Furthermore, baseline Cho/NAA ratios and the percent change in Cho/NAA over time have
also been associated with poor prognosis in childhood brain tumors [76–78]. Lower Cho/NAA
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ratios seem to be predictive of the improved outcome in children with recurrent primary brain
tumors, and should be evaluated as a prognostic indicator in newly diagnosed childhood brain
tumors [76].
The Chot/Cren ratios also significantly decreased (p< 0.05) after OKN-007 treatment in
responsive animals compared to untreated pGBM at the end phase of tumor progression (Fig
4C), indicating that the drug was also capable of decreasing tumor cell proliferation in ~50% of
animals in this pediatric glioma model. The 1H-MRS results were also confirmed with IHC
that showed significantly lower (p< 0.05) immunoexpression of Ki-67 (cell proliferation
marker) in the OKN-007–R treated group compared to untreated animals (Fig 7C).
Diffusion-weighted imaging (DWI) represents another promising imaging tool for tissue
characterization, prediction, and the evaluation of therapeutic response in oncology [79]. DWI
is routinely used to measure microscopic, random translational motion of water molecules
within tissues. Any alterations in the tissue structure that disrupt the barriers of water diffusion,
such as the breakdown of cell membranes or damage to fibers, would lead to changes in the dif-
fusion properties within these regions. These diffusion characteristics can be quantified by esti-
mating the ADC (Apparent Diffusion Coefficient). In tumors, ADC values can differentiate the
cellular mechanisms involved in tumor development as well as responses to treatment such as
cell proliferation, apoptosis, and/or necrosis [80]. Both intra- and extracellular spaces and their
exchange contribute to the measured ADC [81]. DWI has also a tremendous potential for
monitoring early changes in tumor cellularity that are thought to be reflective of treatment
response [81]. As cellular density increases, the added tortuosity to extracellular mobility paths
reduces water mobility and, consequently, the ADC value [82]. Processes that degrade cellular
integrity, such as necrosis caused by therapy or tumor growth, are thought to increase the ADC
of tissue [82]. Successful treatment of a tumor with a cytotoxic agent will result in significant
damage to the tumor cells in the form of a loss of cell membrane integrity with a subsequent
reduction in tumor cell density. This has a net effect of increasing the fractional volume of the
interstitial space because of cell loss, resulting in an increase in the mobility (diffusion) of water
within the damaged tumor tissue [81].
In our study, the untreated group showed significantly higher (p< 0.01) normalized ADC
values for the tumor region when compared to the normal mice brain (Fig 5G). The OKN-
007–R treated group showed significantly higher normalized ADC values than the untreated
group (p< 0.05) and normal mice brains (p< 0.001). Interestingly, all OKN-007 treated ani-
mals were responsive to the therapy based on the ADC ratios when compared to the untreated
group. The observed increase in water ADC following therapy is directly related to the number
of tumor cells killed and is thought to be due to the liberation of water into the extracellular
space [82].
Arterial spin labeling (ASL) is a non-invasive magnetic resonance technique for tissue per-
fusion quantification without the application of contrast media. Perfusion is defined as the
amount of blood delivered to capillary beds in a given tissue per unit time. Delivery of blood to
a capillary bed is a critical indicator of tissue viability and function, and the analysis of perfu-
sion [83], which has markedly contributed to the understanding of physiological and patholog-
ical processes in the human body [84]. Furthermore, the ASL technique has been useful for
monitoring the effects of agents designed to modulate tumor blood flow and oxygenation (e.g.,
carbogen gas) [85], and for evaluating and guiding the use of anti-angiogenic agents [42].
Antiangiogenic therapy might affect tumor vessels in 3 different ways: no effect at all; exces-
sive destruction of blood vessels and a reduction in perfusion leading to increased hypoxia,
necrosis, and/or invasion; or after pruning of some abnormal vessels the overall structure of the
remaining tumor vessels may resemble normal vessels, which potentially results in an increase
in absolute blood perfusion [86]. In this study, we measured the changes in normalized relative
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cerebral blood perfusion (rCBF) in normal athymic mouse brains, and in untreated and
OKN-007 treated IC-3752GBM pGBMmice, using the ASL perfusion MRI technique. The
untreated group showed significantly lower (p< 0.0001) rCBF values for the tumor region
when compared to the normal mice brain (Fig 6G). The OKN-007–R treated group showed sig-
nificantly higher rCBF values compared to the untreated group (p< 0.05) and significantly
lower than normal mice brains (p< 0.001). Interestingly, the drug did not seem to affect the
normal perfusion of the brain, as no differences were found between values in the contralateral
regions of OKN-007-R and OKN-007-NR and untreated animals (Fig 6G), being consistent
with the findings from previous research studies in OKN-007-treated C6 gliomas [22]. Our
results also corroborate with the literature that indicates that glioblastomas have lower blood
perfusion rates than that of the surrounding normal brain because of their inefficient, irregular
vessels that are leaky and dilated with a haphazard pattern of interconnection [86].
The positive effect of OKN-007 on perfusion and diffusion properties in IC-3752GBM
pGBM bearing mice indicates a promising influence of the drug on tumor microvasculature,
which was also shown previously in a rat adult glioma model by our group [15]. In our study,
we were also able to demonstrate that OKN-007 acts as an antiangiogenic agent in the IC-
3752GBM pGBMmodel. To support this notion, microvessel density (MVD) was significantly
lower (p< 0.05) in the OKN-007–R treated group than in the untreated group (Fig 8C). The
normalization of tumor vasculature is a necessary step for cancer therapies [87]. This effect
may be mediated by the anti-inflammatory properties of OKN-007. Indeed, alterations to
inflammatory pathways can modify angiogenesis [88], and inflammatory mediators are known
to modulate blood—brain barrier permeability [89]. Therefore it could be expected from the
anti-inflammatory properties of nitrone compounds, that administration of OKN-007 posi-
tively altered the integrity and function of the microvascular bed at the tumor site, conse-
quently increasing the ADC ratios and rCBF values in responsive treated animals.
We also assessed the effect of OKN-007 regarding the immunoexpression of tumor signal-
ing molecules such as PDGFRα, SULF2, and decorin in the IC-3752GBM pGBMmodel.
Although childhood and adult HGGs share related histopathological characteristics, recent
studies have shown substantial differences in the molecular features underlying pediatric and
adult HGGs. The epidermal growth factor receptor is the predominant receptor tyrosine kinase
targeted by both amplification and mutation in adult glioblastomas [90]. In contrast, PDGFRα
is the most frequent target of focal amplification in pediatric HGGs arising within and outside
the brainstem [20–23], and somatic mutations of PDGFRα have been recently reported in
pediatric HGGs [22–24]. Another study revealed that the high expression of phosphorylated
PDGFRα has a significant association with malignant histology in pediatric gliomas [91]. The
expression of PDGFRα has also been demonstrated in medulloblastomas and primitive neu-
roectodermal tumors, and an increase in PDGFRα gene copy numbers seems to be associated
with poor survival in these tumors [92]. The high levels of % PDGFR-α observed in specific
high-intensity ROIs may occur because the mice are 2–3 month-old mice which are still adoles-
cents, and it is known that normal brain tissue may have some areas of high PDGFR-α during
development [93].
SULF2, a heparan sulfate endosulfatase, has been associated to different types of cancers
including lung [94], breast [95], liver [96], gastric [97], and brain tumors [98]. In brain cancer,
SULF2 has been 7directly implicated in driving tumorigenesis in murine and human malignant
gliomas [99]. The SULF2 protein is highly expressed in primary human GBM, and SULF2 lev-
els are inversely related to heparan sulfate proteoglycan (HSPG) 6O-sulfation in a murine
model for GBM [99]. SULF2 gene expression is also significantly positively correlated with
PDGFRα expression [25]. Furthermore, the ablation of SULF2 decreases tumor growth,
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prolongs host survival and decreases the activity of PDGFRα, as well as related downstream
signaling pathways in human and mouse malignant gliomas [99].
Decorin is a small proteoglycan found in the extracellular matrix of a variety of tissues and
cell types [25,100]. It interacts with a diversity of proteins that are involved in matrix assembly
[101] and in the regulation of fundamental biological functions such as cell attachment [102],
migration [103], and proliferation [104]. Decorin inhibits cell proliferation in several tumor
cell types, including ovarian [101], liver [26], and brain tumor cells [105]. Similarly to SULF2,
decorin is also associated to the PDGFRα pathway [26]. Interestingly, decorin does not
Fig 12. Schematic representation of possible mechanism of action of OKN-007 in IC3752 pGBM tumor bearingmice.Heparan sulfate proteoglycans
(HSPG) consist of a protein core and heparan sulfate (HS) chains consisting of linear carbohydrate chains of repeating disaccharide units. Dependent on the
HSPG core protein, HSPGs are found at the cell surface (1), in the extracellular matrix (2), or in secretory vesicles [98]. Essential for their function in cell
signaling, the HS chains undergo extensive post-translational modifications, including sulfation on the 6-O- position of glucosamine [19]. By removing 6-O-
sulfates on HS chains and mobilizing protein ligands from HSPG sequestration in the extracellular environment (3), the SULF-2 can increase the solubility of
a variety of growth factors (e.g. PDGF) (4) thus increasing the activation of PDGFR-α and downstream signaling pathways in tumor cells (5) [98]. Similarly to
SULF2, decorin is also associated to the PDGFRα pathway. Interestingly, decorin does not co-localize with PDGFRα, but binds directly to its natural ligand
PDGF, directly blocking the activity of PDGFRα (6) [104]. Our current data showed that OKN-007 was able to decrease the immunoexpression of SULF2 (7)
and PDGFRα (8), and increase the expression of decorin (9) in IC3752 pGBM tumor bearing mice, which may be also associated to the inhibition of tumor
angiogenesis and cell proliferation (10) also observed in OKN-007 treated animals. SO3-: sulfate, PDGF: Platelet-derived growth factor. The schematic is a
modification of combined schemes obtained from Oncotarget, 3(5): 568–575, Phillips JJ (2012) [98] (With permission from Impact Journals), and from FEBS
Journal, 280(10):2150–2164, Baghy K et al., (2013) [104] (With permission from JohnWiley and Sons).
doi:10.1371/journal.pone.0134276.g012
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colocalize with PDGFRα, but binds directly to its natural ligand PDGF, directly blocking the
activity of PDGFRα [104]. Furthermore, it is known that decorin antagonizes the angiogenic
network [106] due to the inhibition of the production of VEGF (vascular endothelial growth
factor) by tumor cells and can directly blocking of VEGFR2 (vascular endothelial growth factor
receptor-2) at the same time [107].
Our current data showed that OKN-007 was able to significantly decrease the immunoex-
pression of SULF2 (p< 0.05) in responsive mice compared to untreated animals, which has
also been recently demonstrated in hepatocellular cancer cells [19]. Furthermore, OKN-007
was able to significantly decrease the immunoexpression of PDGFRα (p< 0.05) and signifi-
cantly increase the expression of decorin (p< 0.05) in responsive IC-3752GBM pGBM tumor
bearing mice, compared to untreated animals, which may be also associated to the inhibition of
tumor angiogenesis and cell proliferation which was also observed in the OKN-007-R treated
animals from this study. Fig 12 depicts the possible mechanism-of-action of OKN-007 in
pGBM.
Conclusions
The data taken as a whole indicates that OKN-007 may possibly be an effective anti-cancer
agent for some patients with pHGGs by inhibiting cell proliferation and angiogenesis, poten-
tially via the PDGFRα pathway, and could be considered as an additional therapy for pediatric
brain tumor patients. Currently, OKN-007 is an investigational drug in phase Ib/IIa clinical tri-
als for recurrent adult GBM patients. Our future plan is to conduct clinical trials in pGBM
patients using OKN-007 as an adjunct therapy to possibly help inhibit tumor growth associated
with this devastating disease in children.
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